Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $9M | $24M | $133M | $18M | $70M | — |
| Enterprise Value | $29M | $33M | $47M | $137M | $70M | $70M | — |
| P/E Ratio → | -0.10 | — | — | — | — | 12.10 | — |
| P/S Ratio | 0.36 | 0.61 | 0.75 | 2.49 | 0.28 | 1.83 | — |
| P/B Ratio | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.16 | 1.45 | 2.56 | 1.09 | 1.84 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 62.8% | 62.8% | 67.0% | 77.6% | 79.0% | 76.3% | — |
| Operating Margin | -198.0% | -198.0% | -156.3% | -147.9% | -49.9% | -32.7% | — |
| Net Profit Margin | -188.8% | -188.8% | -81.4% | -150.8% | -58.8% | -32.4% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -26.1% |
| ROA | -118.4% | -118.4% | -50.0% | -131.0% | -83.2% | -62.4% | -1.6% |
| ROIC | — | — | — | — | -122.9% | — | — |
| ROCE | — | — | -496.1% | -1257.8% | — | -322.2% | -26.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 8.57 |
| Debt / EBITDA | — | — | — | — | — | — | 0.85 |
| Net Debt / Equity | — | — | — | — | — | — | 6.20 |
| Net Debt / EBITDA | — | — | — | — | — | — | 0.61 |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -10.23 | -6.60 | -7.50 | -2.38 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.33 | 0.33 | 1.44 | 0.99 | 0.57 | 1.18 | 0.15 |
| Quick Ratio | 0.26 | 0.26 | 1.26 | 0.90 | 0.52 | 1.09 | 0.15 |
| Cash Ratio | 0.14 | 0.14 | 0.82 | 0.58 | 0.10 | 0.82 | 0.15 |
| Asset Turnover | — | 0.97 | 0.98 | 0.75 | 1.25 | 0.97 | — |
| Inventory Turnover | 2.12 | 2.12 | 3.12 | 1.94 | 3.49 | 3.33 | — |
| Days Sales Outstanding | — | 94.69 | 81.09 | 124.20 | 166.81 | 65.21 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 8.3% | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $502969 | $149811 | $94885 | $71783 | $287500 | $287500 |
Critical liquidity depletion risk
Based on reported figures, Allurion trades at a price-to-sales multiple of 0.36, a valuation level that suggests the market is pricing in a high probability of insolvency rather than future growth, especially when compared to broader med-tech sector averages that typically command significantly higher premiums.
The current P/S multiple indicates that investors have largely abandoned the growth narrative, viewing the company as a distressed asset. This valuation compression appears to be a direct response to the company's inability to maintain revenue scale in the face of GLP-1 market dominance.
As reported in financial statements, the company's operating margin has plummeted to -198.01%, a figure that highlights the structural inability of the current business model to cover its fixed cost base, which remains disproportionately high relative to the shrinking revenue generated from its balloon kits.
The stark disconnect between gross margins, which have shown volatility, and the deeply negative operating margins suggests that the company's sales and marketing infrastructure is failing to achieve the necessary scale. This trend implies that without a radical reduction in operating expenses, the firm will continue to consume capital at an unsustainable rate.
According to recent quarterly data, the cash conversion cycle has fluctuated significantly, reaching 64 days in 2026Q1, which indicates that the company is struggling to manage its inventory and receivables effectively during a period of sharp revenue contraction and shifting market demand for its weight-loss solutions.
The high days-in-inventory and days-sales-outstanding metrics suggest that the company is facing difficulty in converting its product shipments into cash. This inefficiency exacerbates the firm's liquidity crisis, as capital remains trapped in unsold inventory rather than being available to fund essential operations.
Based on the most recent quarterly data, Allurion's current ratio has deteriorated to a precarious 0.30, signaling that the company's liquid assets are insufficient to cover its short-term obligations, a trend that warrants immediate investor concern regarding the firm's ability to maintain its ongoing operations.
The rapid decline in the current ratio reflects a severe depletion of cash reserves, leaving the company with little cushion to navigate its current operational challenges. This liquidity position suggests that the firm may be forced to seek highly dilutive financing or pursue a strategic sale to avoid a total depletion of capital.
Investors frequently misapply revenue-based valuation multiples to Allurion, failing to account for the fact that in a distressed med-tech scenario, the company's cash runway and burn rate are far more predictive of equity value than top-line growth or traditional price-to-sales ratios.
Focusing on revenue multiples obscures the reality that the company's primary constraint is its $5.4 million cash balance rather than its market share. Analysts should instead prioritize a 'liquidation-adjusted' valuation or a cash-burn-to-runway analysis to better assess the risk of total capital loss.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALUR stock.
Allurion Technologies Inc.'s current P/E ratio is -0.1x. The historical average is 12.1x.
Based on historical data, Allurion Technologies Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
Allurion Technologies Inc. has 62.8% gross margin and -198.0% operating margin.